Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

MPO inhibitor PF-1355 demonstrates significant attenuation of cardiovascular and renal disorders

Nov. 22, 2013

European Commission approves Prilocaine Lidocaine Plethora for premature ejaculation

Nov. 19, 2013

Toray Industries divulges novel soluble epoxide hydrolase inhibitors

Nov. 18, 2013

Kyowa Hakko Kirin discontinues phase II studies of bardoxolone methyl

Nov. 12, 2013

Keryx Biopharmaceuticals provides update from safety extension study of Zerenex

Nov. 12, 2013

New Hsp70 inducers presented by scientists in the Netherlands

Nov. 11, 2013

Phase II trial of Zerenex in NDD-CKD meets all primary and key secondary endpoints

Nov. 7, 2013

Genkyotex begins multinational phase II study of NOX inhibitor

Nov. 5, 2013

Development of Kremezin discontinued in the U.S. and Europe

Oct. 31, 2013

Sophiris begins dosing in PLUS-1 phase III trial of PRX-302

Oct. 30, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 9, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...